1-5 of 5
Gregory Hogan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser
Journal: Blood
Blood (2023) 142 (Supplement 1): 225.
https://doi.org/10.1182/blood-2023-181007
Published: 2023
Journal Articles

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Ákos Nagy, Bence Bátai, Gregory Hogan, Jacob J. Chabon, Mikayla Troke, Lance Riley, Andre Schultz, Sandra Close, Maximilian Diehn, Donát Alpár, Botond Timár, Ash A. Alizadeh, David M. Kurtz, Csaba Bödör
Journal: Blood
Blood (2023) 142 (Supplement 1): 1626.
https://doi.org/10.1182/blood-2023-189824
Published: 2023
Journal Articles

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Mark Roschewski, Liza Lindenberg, Esther Mena, Rahul Lakhotia, Christopher Melani, Seth M. Steinberg, Andre Schultz, Gregory Hogan, Jake J. Chabon, Sandra Close, Maximilian Diehn, Brian J. Sworder, David M. Kurtz, Ash A. Alizadeh, Wyndham H. Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 192.
https://doi.org/10.1182/blood-2023-180007
Published: 2023
Journal Articles

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David M. Kurtz, Gregory Hogan, Andre Schultz, Jacob J. Chabon, Ash A. Alizadeh, Karin Havenith, Sara Samari, Tim Kopotsha, Luqiang Wang, Yajuan Qin, Ying Wang, Serafino Pantano
Journal: Blood
Blood (2023) 142 (Supplement 1): 3133.
https://doi.org/10.1182/blood-2023-179977
Published: 2023
Journal Articles

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Brian J. Sworder, Sang Eun Yoon, Seok Jin Kim, Andre Schultz, Gregory Hogan, Sandra Close, Jacob J. Chabon, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh, Won Seog Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 69.
https://doi.org/10.1182/blood-2023-187650
Published: 2023